Business

Except for their use in military reconnaissance, unmanned aircraft have been seen mainly as expensive toys. But as technologies mature, Ned Stafford asks when drones are set to go commercial.

As US biotechnology companies seek to expand or relocate their operations abroad, Paris is pitching itself as a scientifically strategic location. Rex Dalton reports.

The corridors of power in the United States are ringing with the phrase 'cap and trade'. But when will carbon markets arrive in America — and what will they look like? Emma Marris investigates.

Physicists at the University of Cambridge are leading a revolution in how data can best be displayed. Katharine Sanderson reports.

Sophisticated new genetic tests face an uncertain future — unless they can win clear-cut approval from regulators, insurers and, most importantly, doctors. Virginia Gewin reports.

Technology companies across the United States are under investigation for manipulating the timing of their bosses’ stock options. Heidi Ledford reports.

Two years after a radical change that brought India's patent laws into line with international trading rules, the country's drug makers are taking a new direction. Apoorva Mandavilli reports.

A drug-trial failure leaves Pfizer in search of a new corporate strategy to deal with the post-blockbuster age, as Meredith Wadman reports.

The Pentagon is sinking millions of dollars into developing the next generation of supercomputers — and plans to let non-military scientists and engineers share the benefits. Heidi Ledford reports.

A spin-off from a UK university has established a solid niche as a leading supplier of microsatellites. But taking the company to the next level is a challenge. Geoff Brumfiel reports.

The job of cleaning up Britain's nuclear plants is up for auction — so who might profit from the newly privatized industry? Andrea Chipman reports.